Camurus reports positive topline results for CAM2056, semaglutide monthly depot
Camurus (NASDAQ: CAMX) reported positive topline Phase 1b results for CAM2056, a monthly FluidCrystal semaglutide depot, in 80 participants with overweight or obesity on Nov 10, 2025. CAM2056 delivered dose-dependent reductions in body weight, A1c and fasting glucose that were comparable to or exceeded weekly semaglutide to Day 85.
Key data: weight -9.3% for CAM2056 10 mg vs -5.2% for weekly semaglutide (treatment diff -4.1%, p=0.008); A1c -0.44% for CAM2056 with treatment diff -0.32% (p<0.001). Safety was generally consistent with weekly semaglutide, though the highest initiation cohort had more frequent/severe events. A Phase 2b study is planned.
Camurus (NASDAQ: CAMX) ha riportato risultati positivi di topline nello studio di fase 1b per CAM2056, un deposito mensile di semaglutide FluidCrystal, in 80 partecipanti con sovrappeso o obesità, il 10 novembre 2025. CAM2056 ha mostrato riduzioni dose-dipendenti del peso corporeo, dell'A1c e della glicemia a digiuno che sono state paragonabili o superiori a quelle del semaglutide settimanale fino al Day 85.
Dati chiave: peso -9,3% per CAM2056 10 mg contro -5,2% per semaglutide settimanale (differenza di trattamento -4,1%, p=0,008); A1c -0,44% per CAM2056 con differenza di trattamento -0,32% (p<0,001). La sicurezza è risultata generalmente coerente con quella del semaglutide settimanale, sebbene il gruppo iniziale più alto abbia registrato eventi più frequenti/more severi. È previsto uno studio di fase 2b.
Camurus (NASDAQ: CAMX) informó resultados positivos de fase 1b en la línea superior para CAM2056, un depósito mensual de semaglutida FluidCrystal, en 80 participantes con sobrepeso u obesidad el 10 de noviembre de 2025. CAM2056 mostró reducciones dosis-dependientes en peso corporal, A1c y glucosa en ayunas que fueron comparables o superiores a las de la semaglutida semanal hasta el Día 85.
Datos clave: peso -9,3% para CAM2056 10 mg frente a -5,2% para semaglutida semanal (diferencia de tratamiento -4,1%, p=0,008); A1c -0,44% para CAM2056 con diferencia de tratamiento -0,32% (p<0,001). La seguridad fue generalmente consistente con la semaglutida semanal, aunque la cohorte de inicio más alta tuvo eventos más frecuentes/graves. Se planifica un estudio de fase 2b.
Camurus (NASDAQ: CAMX)은 2025년 11월 10일 80명의 과체중 또는 비만 참가자를 대상으로 한 1b상 상단선에서 CAM2056의 긍정적 결과를 발표했다. CAM2056은 체중, A1c 및 공복 혈당의 용량 의존적 감소를 보여주었으며 이는 매주 주사되는 세마글루타이드를 Day 85까지 비슷하거나 더 우수하게 나타냈다.
주요 데이터: 체중 -9.3% (CAM2056 10 mg) 대 -5.2% (주간 세마글루타이드) 치료 차이 -4.1%, p=0.008; A1c -0.44% CAM2056의 치료 차이 -0.32% (p<0.001). 안전성은 주간 세마글루타이드와 일반적으로 일치했으나 최고 초기 코호트에서 더 자주/심한 사건이 있었다. 2b상 연구가 계획되어 있다.
Camurus (NASDAQ: CAMX) a publié des résultats positifs de ligne de tête de phase 1b pour CAM2056, un dépôt mensuel de semaglutide FluidCrystal, chez 80 participants en surpoids ou obèses, le 10 novembre 2025. CAM2056 a produit des réductions dose-dépendantes du poids corporel, de l'A1c et de la glycémie à jeun qui étaient comparables ou supérieures au semaglutide hebdomadaire jusqu'au jour 85.
Donnees clés: poids -9,3% pour CAM2056 10 mg contre -5,2% pour le semaglutide hebdomadaire (différence de traitement -4,1%, p=0,008); A1c -0,44% pour CAM2056 avec une différence de traitement -0,32% (p<0,001). La sécurité était généralement conforme à celle du semaglide hebdomadaire, bien que la cohorte de démarrage la plus élevée ait eu des événements plus fréquents/sévères. Une étude de phase 2b est planifiée.
Camurus (NASDAQ: CAMX) berichtete positive Topline-Ergebnisse aus der Phase-1b für CAM2056, ein monatliches FluidCrystal Semaglutide Depot, bei 80 Teilnehmern mit Übergewicht oder Adipositas am 10. November 2025. CAM2056 zeigte dosisabhängige Reduktionen des Körpergewichts, A1c und Nüchternblutzucker, die mit dem wöchentlichen Semaglutid bis Tag 85 vergleichbar oder überlegen waren.
Wichtige Daten: Gewicht -9,3% für CAM2056 10 mg vs -5,2% für wöchentliches Semaglutid (Behandlungsunterschied -4,1%, p=0,008); A1c -0,44% für CAM2056 mit Behandlungsunterschied -0,32% (p<0,001). Die Sicherheit war im Allgemeinen konsistent mit dem wöchentlichen Semaglutid, obwohl die höchste Startkohorte häufiger/schwerere Ereignisse hatte. Eine Phase-2b-Studie ist geplant.
Camurus (NASDAQ: CAMX) أصدرت نتائج إيجابية في خط النهاية الأولي من المرحلة 1b لـ CAM2056، وهو مستودع شهري من semaglutide FluidCrystal، في 80 مشاركاً يعانون من زيادة الوزن أو السمنة في 10 نوفمبر 2025. حقق CAM2056 انخفاضات تعتمد على الجرعة في وزن الجسم وA1c والجلوكوز الصائم وكانت قابلة للمقارنة مع أو تفوق semaglutide الأسبوعي حتى اليوم 85.
البيانات الرئيسية: الوزن -9.3% لـ CAM2056 10 mg مقابل -5.2% لـ semaglutide الأسبوعي (اختلاف العلاج -4.1%، p=0.008); A1c -0.44% لـ CAM2056 مع اختلاف علاج -0.32% (p<0.001). الأمان كان بشكل عام متسقاً مع semaglutide الأسبوعي، على الرغم من أن المجموعة الأعلى بدءاً شهدت أحداث أكثر تكراراً/أشدّ. مخطط إجراء دراسة من المرحلة 2b.
- Weight -9.3% for CAM2056 10 mg at Day 85
- Treatment difference -4.1% vs weekly semaglutide (p=0.008)
- A1c -0.44% for CAM2056; treatment difference -0.32% (p<0.001)
- Monthly dosing enabled by extended-release profile
- Similar Cmax achieved with a four times higher monthly dose
- Highest initiation-dose cohort showed more frequent and more severe adverse events
- Study size was small: 80 participants (Phase 1b), limiting generalizability
- Similar Cmax required a fourfold monthly dose versus weekly semaglutide
Insights
Phase 1b shows monthly semaglutide formulation with greater short-term weight and A1c reductions versus weekly semaglutide.
CAM2056 produced dose-dependent reductions in body weight and A1c to Day
The safety profile was broadly consistent with weekly semaglutide across most cohorts, with mostly mild to moderate transient gastrointestinal events and few injection site reactions. The highest initiation-dose cohort showed a tendency toward more frequent and more severe events; a small number of participants discontinued early (one to two per CAM2056 arm, two for weekly semaglutide, n=16 cohorts reported). These safety signals warrant close monitoring as dosing accelerates.
Key items to watch include the planned Phase
- CAM2056 showed weight and A1c reductions comparable to or exceeding those seen for weekly semaglutide (Wegovy®)
-
Results include a
9.3% weight reduction with CAM2056 vs.5.2% with weekly semaglutide at Day 85 - Safety and tolerability were consistent with weekly semaglutide
- CAM2056 has potential for monthly dosing with rapid initiation
"We are very pleased with the Phase 1b data showing that CAM2056 is well tolerated and achieves dose-dependent reductions in body weight and A1c, matching or exceeding those observed with weekly semaglutide," says Fredrik Tiberg, President & CEO, CSO of Camurus. "The study data suggest that CAM2056 allows rapid dose titration without compromising tolerability, whilst also allowing convenient monthly dosing. Further evaluation of CAM2056 is planned in an upcoming Phase 2b study."
CAM2056 is a monthly subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist formulated with Camurus' proprietary FluidCrystal® technology.
Topline results from the Phase 1b study include:
- CAM2056 achieved a similar maximum plasma concentration (Cmax) at a four times higher monthly dose compared to weekly semaglutide. Additionally, CAM2056 showed longer time to Cmax and an extended-release profile suitable for monthly dosing.
- CAM2056 provided dose-dependent reductions in body weight, A1c and fasting glucose, comparable to or exceeding those with weekly semaglutide to end of treatment, Day 85
- The mean weight change from baseline to Day 85 for CAM2056 10 mg was -
9.3% compared to -5.2% for weekly semaglutide dosed as per prescribing information. The treatment difference was -4.1% (-7.1% , -1.1% ), p=0.008. CAM2056 reached similar weight reduction after 3 months as weekly semaglutide after 5 months. - The mean A1c change from baseline to Day 85 was -
0.44% , after the last 10 mg dose. The treatment difference between CAM2056 and weekly semaglutide was -0.32% (-0.50% , -0.14% ), p<0.001. - The safety and tolerability profile of CAM2056 was favorable, despite higher initial doses and more rapid dose escalation compared to weekly semaglutide. Only the last cohort with the highest initiation dose showed a tendency for more frequent and severe events. For all other cohorts, the safety profile was consistent with weekly semaglutide dosed as per prescribing information. The most common adverse events were mild to moderate and transient gastrointestinal adverse (GI). Only a limited number of injection site reactions were reported in the study, all of which were mild and transient. A small number of participants stopped treatment early in these cohorts: one to two per arm for CAM2056, and two for weekly semaglutide (n=16).
FluidCrystal® is a registered trademark of Camurus. Wegovy® is a registered trademark of Novo Nordisk.
For more information
Fredrik Tiberg, President & CEO, CSO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About CAM2056 and semaglutide solution for injection
CAM2056 is a long-acting, subcutaneous semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. The weekly semaglutide solution for injection is marketed for weight management (Wegovy®)1 and to improve glycemic control in type 2 diabetes mellitus patients (Ozempic®). CAM2056 is formulated with Camurus' proprietary FluidCrystal® technology, which is commercially validated and used in marketed pharmaceutical products3,4.
About the Phase 1b study
The Phase 1b study was a multi-arm, repeated-dose, randomized, active-controlled study, with a separate dose-escalation part, designed to assess the pharmacokinetics, pharmacodynamics, and safety and tolerability of CAM2056 in 80 adult participants (16 in each cohort) with overweight or obesity (BMI=27 to 39.9) who were otherwise healthy. In the first part, participants were randomized 1:1:1 to weekly semaglutide and two formulations of CAM2056. The second part of the study investigated escalating starting and monthly doses with CAM2056 to explore dose response, safety and tolerability. Treatment with CAM2056 was in all cohorts started with two biweekly initiation doses followed by two monthly doses, while weekly semaglutide was administered for five months according to the prescribing information (Wegovy®)1. The highest CAM2056 initiation dose was 5 mg and the highest monthly dose was 15 mg. Camurus plans to start a Phase 2b trial of CAM2056 in 2026, featuring longer treatment duration and elevated doses.
About obesity and type-2 diabetes
Obesity is a significant global health issue associated with various comorbidities, including type 2 diabetes, cardiovascular diseases, steatohepatitis, and chronic kidney disease. It is estimated that over 1 billion individuals globally were affected by obesity in 2022, representing approximately one in eight people worldwide. This figure comprises nearly 880 million adults and 159 million children and adolescents aged 5 to 19 years. Since 1990, adult obesity has more than doubled, and it has quadrupled among children and adolescents. This increase has notable implications for societies and healthcare systems worldwide.4
Type 2 diabetes is a long-term condition in which the body does not produce sufficient insulin or becomes resistant to insulin, resulting in elevated blood glucose levels. Its development is associated with factors such as excess body weight, limited physical activity, dietary choices, and genetic predisposition. A1c is regarded as a standard method for assessing long-term glycemic control.5,6
About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across
References
- Wegovy® SmPC
- Buvidal® SmPC
- Oczyesa® SmPC
- World Health Organization (WHO), Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight .
- Center for Disease Control (CDC). Diabetes Risk Factors. https://www.cdc.gov/diabetes/risk-factors/index.html .
- CDC. A1C Test for Diabetes and Prediabetes. https://www.cdc.gov/diabetes/diabetes-testing/prediabetes-a1c-test.html .
This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the managing director, at 8:00 am CET on 10 November 2025.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
|
Press release |
View original content:https://www.prnewswire.com/news-releases/camurus-reports-positive-topline-results-for-cam2056-semaglutide-monthly-depot-302609925.html
SOURCE Camurus AB
FAQ
What were the key weight-loss results for CAM2056 (CAMX) in the Nov 10, 2025 Phase 1b study?
How did CAM2056 affect A1c compared with weekly semaglutide in the CAMX study?
Does CAM2056 (CAMX) support monthly dosing and how?
Were there safety concerns with CAM2056 in the Phase 1b study?
What is the clinical development next step for CAM2056 (CAMX)?
How many participants were in the CAM2056 Phase 1b study (CAMX)?
